3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis

Main Article Content

Richard Warren
Dermatology Centre, Salford Royal NHS Foundation Trust and NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

Kristian Reich
Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg Eppendorf, Hamburg, DE

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Richard Langley
Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, CA

Antonio Costanzo
Dermatology Unit Department of Biomedical Sciences, Humanitas University, Milano, IT; Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, IT

Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, JP

Peter Almgren
LEO Pharma A/S, Ballerup, Denmark

Emilia Vacko
LEO Pharma A/S, Ballerup, Denmark

Anna Carlsson
LEO Pharma A/S, Ballerup, Denmark

Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, ON, CA; Department of Dermatology, Queen's University, Kingston, ON, CA; Probity Medical Research, Waterloo, ON, CA

Mette Deleuran
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark

Juan Francisco Silvestre
Dermatology Department, Hospital General Universitario de Alicante, Alicante, Spain

Stefan Weidinger
Department of Dermatology and Allergy, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Keywords

atopic dermatitis, tralokinumab

References

1. Weidinger S, Novak N. Lancet . 2016;387(10023):1109 1122.

2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1409 1431.

3. de Bruin Weller M, et al. Acta Derm Venereol 2021;101:adv00402.

4. Blauvelt A, et al. Poster presented at: American Academy of Dermatology Annual Meeting; March 25 29, 2022, Boston, MA.

5. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190 9622(22)02345 3.

6. Simpson E, et al. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; December 13 14, 2020,Virtual.

7. Chuang Stein C. Pharm Stat 2011; 10:3 7.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.142

Article Details

How to Cite
Warren, R., Reich, K., Simpson, E., Langley, R., Costanzo, A. ., Saeki, H., Almgren, P., Vacko, E., Carlsson, A., Gooderham, M., Deleuran, M., Silvestre, J. F., Weidinger, S., & Blauvelt, A. (2023). 3 years of tralokinumab treatment provides long term disease control as demonstrated by clinically meaningful outcomes in modera te to severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, 7(2), s142. https://doi.org/10.25251/skin.7.supp.142
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>